Skip to Main Content

For the second time in less than two years, Akrevia Therapeutics has changed its name, in conjunction with the news that it has raised more than $100 million in additional venture capital.

The biotech, based in Waltham, Mass., is trying to develop precision cancer treatments that harness the body’s immune system. It was originally called Akreivia, but dropped the first “i” in September 2018 because it was hard to spell and pronounce, according to company executives.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!